Table of Contents
A comparative analysis and assessment of TCR technologies, pipelines and companies from an industry perspective
Therapeutic monoclonal antibodies have become an increasingly successful treatment modality with sales of US$ 65 bln in the year 2012 and with an average (continuous) annual growth rate from 2006 to 2012 of 18.9%. While antibody technologies are steadily evolving, the spectrum of druggable targets for monoclonal antibodies has remained limited to extracellular antigens, albeit including proteins, carbohydrates and glycolipids.
Access to druggable, IP-protected and validated new targets is a major bottleneck in the biopharmaceutical industry. Technologies which can deliver both new targets and the corresponding treatment modality, can expect significant financial acknowledgement.
The T-cell receptor (TCR) has recently emerged as a means to target peptide antigens derived from intracellular proteins, however, in a major histocompatibility complex (MHC)-restricted manner. The first companies have overcome significant technical hurdles in putting together a library of viable new TCR-targeted antigens and establish the corresponding standardized protein- and cell-based therapeutic frameworks.
This report entitled The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry published in Ocotber 2013 describes chances and pitfals in exploiting the opportunities which offers the engineered T-cell receptor as integral part of fusion proteins, antibodies and cellular products. The key success factors are highlighted, the technical challenges described and solutions presented.
Benefits from the report:
• Identify players in the field, from industry and academia;
• Find out which TCR technologies are valued by Big Pharma and Biotech;
• Understand the value of intracellular antigens targeted by the TCR;
• Recognize the challenges of TCR-based therapeutics and their solutions;
• Learn which TCR-based therapeutics are attractive for partnering;
• Find out which TCR therapeutic approaches are not yet tapped.
Get Industry Insights. Simply.
Talk to Ahmad
+1 718 618 4302
Global Autologous Cell Therapy Market: Overview This report provides in-depth region wise and country wise analysis of the autologous cell therapy market. Stakeholders of this report include manufacturers ...
The global top 10 bioprocess technology market is expected to reach USD 71.03 billion by 2021 from USD 39.30 billion in 2016, at a CAGR of 12.4% from 2016 to 2021. On the basis of type, the market is segmented ...
The global stem cell therapy market is estimated to grow at a CAGR of 11.0% during 2016 to 2021 to reach USD 145.8 million by 2021. Growth in the global stem cell therapy market is driven by factors such ...